Keywords: Body: Pelvis, Body: Urogenital, Education Committee: Clinical MRI
Radiomics and genomics have potential to add value in the diagnosis and risk stratification of cancer. Radiomics analyses quantitative imaging biomarkers of tumours in medical images, such as morphological, histogram and texture features, whereas genomics investigates genetic elements of cancer tissue. Combining these into radiogenomics enables the generation of combinations of features, known as signatures, that can predict cancer phenotypes which effect the biological properties and therefore the behaviour of tumours. This presentation examines MRI radiomics and radiogenomics and their use in aiding the screening, detection, classification, treatment, and prognosis of prostate cancer.